Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Shares Outstanding for 16 consecutive years, with $86.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 32.28% to $86.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.2 million through Dec 2025, up 32.28% year-over-year, with the annual reading at $86.2 million for FY2025, 32.28% up from the prior year.
  • Shares Outstanding hit $86.2 million in Q4 2025 for Guided Therapeutics, up from $83.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $86.2 million in Q4 2025 to a low of $1000.0 in Q3 2021.
  • Historically, Shares Outstanding has averaged $30.6 million across 5 years, with a median of $28.4 million in 2021.
  • Biggest five-year swings in Shares Outstanding: crashed 99.99% in 2023 and later skyrocketed 7897000.0% in 2025.
  • Year by year, Shares Outstanding stood at $2000.0 in 2021, then soared by 2429685.75% to $48.6 million in 2022, then grew by 11.34% to $54.1 million in 2023, then grew by 20.38% to $65.1 million in 2024, then surged by 32.28% to $86.2 million in 2025.
  • Business Quant data shows Shares Outstanding for GTHP at $86.2 million in Q4 2025, $83.6 million in Q3 2025, and $78971.0 in Q2 2025.